Psychedelics in Addiction Treatment

Total Page:16

File Type:pdf, Size:1020Kb

Psychedelics in Addiction Treatment Psychedelics in Addiction Treatment Chris Stauffer, MD UCSF & SFVAMC, Dept of Psychiatry Matthew Johnson, PhD Johns Hopkins, Dept of Psychiatry & Behavioral Sciences Mary Cosimano, MSW Johns Hopkins, Behavioral Pharmacology Research Unit Boston | November 8, 2019 Disclosure • No classic psychedelic (e.g., psilocybin, LSD, mescaline) nor MDMA have a current FDA-approved indication for medical use What is a ”PSYCHEDELIC”? • Classic Psychedelics (5HT2A agonists) • Psilocybin • LSD (lysergic acid diethylamide) • Mescaline • DMT (N,N-Dimethyltryptamine) • Empathogen-Entactogen • MDMA • MDA • Dissociatives • Ketamine Why PSILOCYBIN? Coffee Psilocybe cubensis Psilocybin (+ >200 other species Caffeine of mushroom) Maria Sabina, Mazatec curandera Robert Gordon Wasson Psilocybe mexicana Pharmaceutical Psilocybin 1959: Isolated from P. Mexicana 1960s: Produced by Sandoz, 100’s of legal administrations worldwide Brown RT, et al. Clin Pharmacokinet. 2017;56(12):1543-1554. Passie T, et al. Addict Biol. 2002;7(4):357-364. 1970: Controlled Substances Act Psilocybin - DEA Schedule 1 substance 1980’s: animal work 1990’s: FDA approves human dose-response study (UNM) 2001: First modern-day psilocybin clinical trial (OCD, UArizona) Relative Harm of Drugs of Potential Misuse van Amsterdam J, et. al. Eur Addict Res 2010;16:202–207 Nutt D, et. al. The Lancet 2007, 369:1047-1053 National Survey on Drug Use & Health The Substance Abuse & Mental Health Services Administration (SAMHSA) • Pooled 2008-2012, n > 191,832 (7,550 lifetime psilocybin use) • Respondents ≥18yo Lifetime Hx Psilocybin Use vs No Hx Psychedelic Use Psychological Suicidal Suicidal Suicide distress thinking planning attempt past month past year past year past year .70 (.60-.81)*** .76 (.64-.90)** .54 (.36-.82)** .58 (.35-.94)* weighted odds ratios (95% confidence intervals), *p<.05, **p<.01, ***p<.0001 Hendricks, Johnson, & Griffiths. J Psychopharmacol. 2015; 29(9):1041-1043. Placebo Psilocybin Petri G, Expert P, Turkheimer F, Carhart-Harris R, Nutt D, Hellyer J, & Vaccarino F. (2014) Homological scaffolds of brain functional networks. J. R. Soc. Interface. 11:20140873. PSILOCYBIN –Current Clinical Trials (33) •Major Depressive Disorder •Cancer-related anxiety •Migraine/Cluster Headache •OCD •Anorexia •Substance Use Disorders (Nicotine, Alcohol, Cocaine) Psychedelics in Addiction Treatment Matthew W. Johnson, Ph.D. Associate Professor Behavioral Pharmacology Research Unit Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine • Psilocybin in >100 mushroom species • “Classic psychedelic” – Psilocybin – LSD – Mescaline (peyote) – DMT (ayahuasca) 1940s – 1970s • Psychedelics were intensely investigated as research tools and therapeutics • Promising findings for: – Cancer-related distress – Alcoholism The Dark Ages • Despite promising preliminary findings, human research with psychedelics became largely dormant • Dormancy largely a reaction to the association of LSD with the 1960s counterculture Abuse liability & Risks 2018 • Can cause harm in people with psychosis or predisposition • For anybody, can cause fear, panic, confusion and potentially dangerous behavior • Moderate elevations in pulse & blood pressure • Headaches in day following use • Persisting perceptual changes • No addiction Safety Guidelines 2008 • Assisted in the approval of psychedelic studies by new scientists and universities • Screening, preparation, monitoring, follow-up Mystical Experiences & Lasting Benefit 2006 & 2008 • Safe in this structured setting • Among the 5 most meaningful life experiences for majority of people • Improvements in mood and quality of life >1 year after sessions Psilocybin Dose Effects 2011 • Increasing psilocybin dose has an orderly effect on mystical experience, challenging experience, and long term positive attribution Mystical Experience • About 60% of participants in both studies met criteria for a “complete” mystical experience • Unity • Noetic quality • Sacredness • Sense of transcending time and space • Positive mood • Ineffability Psilocybin Increases Openness 2011 • First experimental study to change a personality dimension • Driven by mystical experience Driven by Mystical Experience Addiction Treatment • Classic psychedelics can be misused but are not addictive Krebs & Johansen (2012) Across studies, LSD nearly doubled the odds that alcoholic patients would be improved at the 1st follow up (N=536) Smoking Cessation Pilot 2014 • Feasibility and safety Pilot Study Timeline • 15 week protocol with weekly meetings • Cognitive behavioral therapy • 3 psilocybin sessions over 8 weeks (20-30 mg/70 kg) • 1st Psilocybin session on target quit date Success Rates Substantially Higher than Typical (Hughes et., 2003; Jorenby et al., 2006; Sykes & Marks, 2001) Mystical Experience in Smoking Cessation 2015 • Greater success in those who had mystical experience • Mystical experience associated with craving reduction Alcohol Dependence Pilot • 10 alcohol-dependent participants • Motivational Enhancement Therapy • 2 sessions of .3 mg/kg and .4 mg/kg psilocybin Survey Study of Alcohol Cessation • 343 people claiming to have quit or reduced smoking as the result of a psychedelic experience • 83% no longer qualified as having a alcohol use disorder Randomized Comparative Efficacy Trial • 80 treatment-resistant smokers • Randomized to psilocybin or nicotine patch • Same cognitive behavior therapy • 1 psilocybin session The Dope Slap Effect “Matt Johnson believes that psychedelics can be used to change all sorts of behaviors, not just addiction. The key, in his view, is their power to occasion a sufficiently dramatic experience to ‘dope-slap people out of their story...’ Psychedelics open a window of mental flexibility in which people can let go of the mental models we use to organize reality.’” Acknowledgments Roland Griffiths, Ph.D. Bill Richards, Ph.D. Mary Cosimano, M.S.W. Albert Garcia-Romeu, Ph.D. Brian Richards, Psy.D. Frederick Barrett, Ph.D. Maggie Klinedinst Robert Jesse Annie Umbricht, M.D Chad Reissig, Ph.D. Peter Hendricks, Ph.D. Katherine MacLean, Ph.D. Haley Sweet Samantha Gebhart Toni White https://hopkinspsychedelic.org Fred Reinholdt, M.A. Leticia Nanda, N.P. Email: [email protected] Eric Richter Grant Glatfelter Janna Bonesteel Crystal Barnhouser Theresa Carbonaro, Ph.D. Patrick Johnson, Ph.D. Jenna Cohen Marylyn Clark Daniel Emory Eric Jackson Heather Cronin Una McCann, M.D. Debbie Allan Kim Nelson T. Cody Swift, M.A. Lilian Salinas Laura Doyle Nathan Sepeda John Clifton Nora Belblidia Dan Evatt, Ph.D. David Nichols, Ph.D. Charles Nichols, Ph.D. Tehseen Noorani, Ph.D. Funding Heffter Research Institute Beckley Foundation Counsel on Spiritual Practices Betsy Gordon Foundation William Harrison National Institute on Drug Abuse Psychedelics in Addiction Treatment Mary Cosimano, MSW Behavioral Pharmacology Research Unit Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Johns Hopkins Center for Psychedelic & Consciousness Research Conducting Psychedelic-Assisted Treatment Mary Cosimano, MSW Director of Clinical Services Are Psychedelic Drugs a Panacea? • Smoking cessation, end-of-life, depression, beginner and long-term meditators • Tom Insel former director of NIMH • Different symptoms - Same mental formations • Excess rigidity in brain • Destructive narratives • Psychedelics work on locked-in conditions The Role of the Guide • Similar for all studies • Each participant assigned 2 guides • Preparation meetings • Psilocybin sessions • Integration meetings Preparatory Meetings • 6 to 8 hours - few days to weeks • Developing trust and rapport • Session logistics • Managing high-dose psilocybin sessions • Set: participant’s internal mental state • Setting: external environment Volunteer on Value of Preparation “Had it not been for the two experienced researchers in the room, I probably would have had a full- blown panic attack and lost the larger experience.” Psilocybin Session ⚫ 8 hour day – Lying on sofa – eyeshades - headphones ⚫ Relax and Let go - Expansion of Consciousness ⚫ The onset of revelatory experiences seems to correspond to my success in remaining relaxed.” ⚫ Majority have Mystical Experience - Interconnectedness ⚫ Difficult experiences not uncommon ⚫ Important and meaningful Integration Meetings • Incorporate experiences into daily life • Key Component of Studies • Easy to dismiss • “Integration is weaving the mystical into the practical.” My Perspective as Guide • Who am I? What is meaning of my life? • Our Connections – to everything – to life • Love is connection - relationships • Love: true nature, authentic self • Guide – exploration with participant • Each a unique exploration – same method Personal Belief • I believe this exploration in combination with the psilocybin sessions and integration, is what leads to reconnection to our true, authentic self— and that helps to find meaning to our lives- • THAT appears to me to be one of the main outcomes of our psilocybin studies. Volunteer Quote • “My single strongest memory will be from the first session when I found myself chasing something that had been eluding me. When I caught it, I discovered that it was me. The subsequent embrace and rejoining seems to me to be the single most powerful event in my life. I feel whole for the first time and able to cope with anything. Apart, “I” was weak and directionless. Listless, really. But together, I’m strong, capable of anything, and just happier.” Tom “Comfortable and Cozy” • 59 year old male • Professional
Recommended publications
  • Hallucinogens - LSD, Peyote, Psilocybin, and PCP
    Hallucinogens - LSD, Peyote, Psilocybin, and PCP Hallucinogenic compounds found in some • Psilocybin (4-phosphoryloxy-N,N- plants and mushrooms (or their extracts) dimethyltryptamine) is obtained from have been used—mostly during religious certain types of mushrooms that are rituals—for centuries. Almost all indigenous to tropical and subtropical hallucinogens contain nitrogen and are regions of South America, Mexico, and classified as alkaloids. Many hallucinogens the United States. These mushrooms have chemical structures similar to those of typically contain less than 0.5 percent natural neurotransmitters (e.g., psilocybin plus trace amounts of acetylcholine-, serotonin-, or catecholamine- psilocin, another hallucinogenic like). While the exact mechanisms by which substance. hallucinogens exert their effects remain • PCP (phencyclidine) was developed in unclear, research suggests that these drugs the 1950s as an intravenous anesthetic. work, at least partially, by temporarily Its use has since been discontinued due interfering with neurotransmitter action or to serious adverse effects. by binding to their receptor sites. This DrugFacts will discuss four common types of How Are Hallucinogens Abused? hallucinogens: The very same characteristics that led to • LSD (d-lysergic acid diethylamide) is the incorporation of hallucinogens into one of the most potent mood-changing ritualistic or spiritual traditions have also chemicals. It was discovered in 1938 led to their propagation as drugs of abuse. and is manufactured from lysergic acid, Importantly, and unlike most other drugs, which is found in ergot, a fungus that the effects of hallucinogens are highly grows on rye and other grains. variable and unreliable, producing different • Peyote is a small, spineless cactus in effects in different people at different times.
    [Show full text]
  • Hallucinogens - LSD, Peyote, Psilocybin, and PCP
    Information for Behavioral Health Providers in Primary Care Hallucinogens - LSD, Peyote, Psilocybin, and PCP What are Hallucinogens? Hallucinogenic compounds found in some plants and mushrooms (or their extracts) have been used— mostly during religious rituals—for centuries. Almost all hallucinogens contain nitrogen and are classified as alkaloids. Many hallucinogens have chemical structures similar to those of natural neurotransmitters (e.g., acetylcholine-, serotonin-, or catecholamine-like). While the exact mechanisms by which hallucinogens exert their effects remain unclear, research suggests that these drugs work, at least partially, by temporarily interfering with neurotransmitter action or by binding to their receptor sites. This InfoFacts will discuss four common types of hallucinogens: LSD (d-lysergic acid diethylamide) is one of the most potent mood-changing chemicals. It was discovered in 1938 and is manufactured from lysergic acid, which is found in ergot, a fungus that grows on rye and other grains. Peyote is a small, spineless cactus in which the principal active ingredient is mescaline. This plant has been used by natives in northern Mexico and the southwestern United States as a part of religious ceremonies. Mescaline can also be produced through chemical synthesis. Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is obtained from certain types of mushrooms that are indigenous to tropical and subtropical regions of South America, Mexico, and the United States. These mushrooms typically contain less than 0.5 percent psilocybin plus trace amounts of psilocin, another hallucinogenic substance. PCP (phencyclidine) was developed in the 1950s as an intravenous anesthetic. Its use has since been discontinued due to serious adverse effects. How Are Hallucinogens Abused? The very same characteristics that led to the incorporation of hallucinogens into ritualistic or spiritual traditions have also led to their propagation as drugs of abuse.
    [Show full text]
  • American Civil Liberties Union
    WASHINGTON LEGISLATIVE OFFICE March 19, 2012 Honorable Patti B. Saris, Chair United States Sentencing Commission One Columbus Circle, N.E. Suite 2-500, South Lobby Washington, D.C. 2002-8002 Re: ACLU Comments on Proposed Amendments to Sentencing Guidelines, Policy Statements, and Commentary due on March 19, 2012 AMERICAN CIVIL LIBERTIES UNION WASHINGTON Dear Judge Saris: LEGISLATIVE OFFICE 915 15th STREET, NW, 6 TH FL WASHINGTON, DC 20005 With this letter the American Civil Liberties Union (“ACLU”) provides T/202.544.1681 commentary on the Amendments to the U.S. Sentencing Guidelines F/202.546.0738 WWW.ACLU.ORG (“Guidelines”) proposed by the Commission on January 19, 2012. The American Civil Liberties Union is a non-partisan organization with more than LAURA W. MURPHY DIRECTOR half a million members, countless additional activists and supporters, and 53 NATIONAL OFFICE affiliates nationwide dedicated to the principles of liberty, equality, and justice 125 BROAD STREET, 18 TH FL. embodied in our Constitution and our civil rights laws. NEW YORK, NY 10004-2400 T/212.549.2500 These comments address four issues that the Commission has asked for OFFICERS AND DIRECTORS SUSAN N. HERMAN public comment on by March 19, 2012. First, the ACLU encourages the PRESIDENT Commission to reject the adoption of the 500:1 MDMA marijuana equivalency ANTHONY D. ROMERO ratio for N-Benzylpiperazine, also known as BZP, (BZP) and make substantial EXECUTIVE DIRECTOR downward revisions to the MDMA marijuana equivalency ratio. Also, we urge ROBERT REMAR the Commission to respect the principles of proportionality and due process in TREASURER deciding how and whether to amend the Guideline for unlawfully entering or remaining in the country.
    [Show full text]
  • Hallucinogens and Dissociative Drugs
    Long-Term Effects of Hallucinogens See page 5. from the director: Research Report Series Hallucinogens and dissociative drugs — which have street names like acid, angel dust, and vitamin K — distort the way a user perceives time, motion, colors, sounds, and self. These drugs can disrupt a person’s ability to think and communicate rationally, or even to recognize reality, sometimes resulting in bizarre or dangerous behavior. Hallucinogens such as LSD, psilocybin, peyote, DMT, and ayahuasca cause HALLUCINOGENS AND emotions to swing wildly and real-world sensations to appear unreal, sometimes frightening. Dissociative drugs like PCP, DISSOCIATIVE DRUGS ketamine, dextromethorphan, and Salvia divinorum may make a user feel out of Including LSD, Psilocybin, Peyote, DMT, Ayahuasca, control and disconnected from their body PCP, Ketamine, Dextromethorphan, and Salvia and environment. In addition to their short-term effects What Are on perception and mood, hallucinogenic Hallucinogens and drugs are associated with psychotic- like episodes that can occur long after Dissociative Drugs? a person has taken the drug, and dissociative drugs can cause respiratory allucinogens are a class of drugs that cause hallucinations—profound distortions depression, heart rate abnormalities, and in a person’s perceptions of reality. Hallucinogens can be found in some plants and a withdrawal syndrome. The good news is mushrooms (or their extracts) or can be man-made, and they are commonly divided that use of hallucinogenic and dissociative Hinto two broad categories: classic hallucinogens (such as LSD) and dissociative drugs (such drugs among U.S. high school students, as PCP). When under the influence of either type of drug, people often report rapid, intense in general, has remained relatively low in emotional swings and seeing images, hearing sounds, and feeling sensations that seem real recent years.
    [Show full text]
  • Hallucinogens
    Hallucinogens What Are Hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and others are synthetic (human-made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes. Hallucinogens are a Types of Hallucinogens diverse group of drugs Classic Hallucinogens that alter perception, LSD (D-lysergic acid diethylamide) is one of the most powerful mind- thoughts, and feelings. altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other Hallucinogens are split grains. into two categories: Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) comes from certain classic hallucinogens and types of mushrooms found in tropical and subtropical regions of South dissociative drugs. America, Mexico, and the United States. Peyote (mescaline) is a small, spineless cactus with mescaline as its main People use hallucinogens ingredient. Peyote can also be synthetic. in a wide variety of ways DMT (N,N-dimethyltryptamine) is a powerful chemical found naturally in some Amazonian plants. People can also make DMT in a lab.
    [Show full text]
  • Programme & Abstracts
    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
    [Show full text]
  • Drug Education Student Booklet
    WHAT YOU NEED TO KNOW STUDENT VERSION CONTENTS What is a drug? 3 How many young people use drugs and alcohol? 4 Drug and alcohol use and the law 6 Making choices 7 How to help a friend who has taken a drug 10 DRS-ABCD: Basic life support flow chart 13 Putting someone in the recovery position 14 How to help a friend or family member with their drug or alcohol use 15 Drugs A-Z Alcohol 17 Benzodiazepines 18 Cannabis 19 Cocaine 20 GHB 21 Hallucinogens 22 Heroin 23 Inhalants 24 Ketamine 25 MDMA/Ecstasy 26 Methamphetamine 27 New psychoactive substances 28 Synthetic cannabinoids 29 Performance and image-enhancing drugs 30 Tobacco & e-cigarettes 31 Polydrug use 32 Notes 33 Glossary 36 More information and sources of help 37 2 WHAT IS A DRUG? Drugs (including alcohol) are substances that affect the way the body functions when they are used. If a drug is illegal it means that it is forbidden by law. Different drugs have different effects on people, and different factors can impact on the experience of drug use. These include: ● the drug itself (e.g. the pharmacological properties of the substance being taken); ● the individual taking the drug (e.g. age, sex, physical and mental health of a person); ● the environment (the setting where the drug is being used, which can be legal, cultural or situational). Drinking two or three beers might be relatively low risk for a healthy adult but the risk of harm increases if they drink on an empty stomach, try to drive a car after drinking, or have a pre- existing health problem.
    [Show full text]
  • From Sacred Plants to Psychotherapy
    From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine).
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Dissertação Final Corrigida
    Universidade Estadual Paulista “Julio de Mesquita Filho” Instituto de Artes ALINE PIRES LUZ A ARTE PSICODÉLICA E SUA RELAÇÃO COM A ARTE CONTEMPORÂNEA NORTE-AMERICANA E INGLESA DOS ANOS 1960: uma dissolução de fronteiras São Paulo 2014 ALINE PIRES LUZ A ARTE PSICODÉLICA E SUA RELAÇÃO COM A ARTE CONTEMPORÂNEA NORTE-AMERICANA E INGLESA DOS ANOS 1960: uma dissolução de fronteiras Dissertação apresentada ao curso de Pós- Graduação em Artes, do Instituto de Artes da Universidade Estadual Paulista – UNESP, como requisito parcial para obtenção do título de Mestre em Artes Visuais, Área de concentração: História da Arte. Linha de Pesquisa: Abordagens Teóricas, Históricas e Culturais da Arte. Orientador: Prof. Dr. Omar Khouri. São Paulo 2014 ALINE PIRES LUZ A ARTE PSICODÉLICA E SUA RELAÇÃO COM A ARTE CONTEMPORÂNEA NORTE-AMERICANA E INGLESA DOS ANOS 1960: uma dissolução de fronteiras Dissertação aprovada como requisito parcial para obtenção do grau de Mestre em Artes Visuais no curso de Pós-Graduação em Artes, do Instituto de Artes da Universidades Estadual Paulista – UNESP, com área de concentração em História da Arte, pela seguinte banca examinadora: __________________________________________ Prof. Dr. Omar Khouri Instituto de Artes (UNESP) – Orientador. __________________________________________ Prof. Dr. Sérgio Mauro Romagnolo Instituto de Artes (UNESP) __________________________________________ Dr. Júlio César Mendonça Pontifícia Universidade Católica – PUC/SP São Paulo, 10 de Junho de 2014 RESUMO Tem-se por objetivo situar a produção de arte psicodélica vinculada ao movimento de contracultura da década de 1960, em relação à chamada arte contemporânea, que se iniciava no mesmo período e que pode ser tomada como uma arte que se deu no âmbito mainstream , por circular nas principais galerias, museus e fazer parte da História da Arte.
    [Show full text]
  • Ritualized Peyote Use Can Facilitate Mental Health, Social Solidarity
    Ritualized Peyote Use Can Facilitate Mental Health, Social Solidarity, and Cultural Survival: A Case Study of the Religious and Mystical Experiences in the Wixárika People of the Sierra Madre Occidental The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Luce, Nathan William. 2020. Ritualized Peyote Use Can Facilitate Mental Health, Social Solidarity, and Cultural Survival: A Case Study of the Religious and Mystical Experiences in the Wixárika People of the Sierra Madre Occidental. Master's thesis, Harvard Extension School. Citable link https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37365056 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Ritualized Peyote Use Can Facilitate Mental Health, Social Solidarity, and Cultural Survival: A Case Study of the Religious and Mystical Experiences in the Wixárika People of the Sierra Madre Occidental Nathan William Luce A Thesis in the Field of Religion for the Degree of Master of Liberal Arts in Extension Studies Harvard University May 2020 Copyright 2020 Nathan William Luce Abstract This paper examines how the Wixárika, or Huichol, as they are more commonly known to the outside world, have successfully engaged in a decade-long struggle to save their ceremonial homeland of Wirikuta. They have fended off a Canadian silver mining company’s attempts to dig mines in the habitat of their most important sacrament, peyote, using a remarkable combination of traditional and modern resistance techniques.
    [Show full text]
  • (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
    pharmaceuticals Review Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact Andreia Machado Brito-da-Costa 1 , Diana Dias-da-Silva 1,2,* , Nelson G. M. Gomes 1,3 , Ricardo Jorge Dinis-Oliveira 1,2,4,* and Áurea Madureira-Carvalho 1,3 1 Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal; [email protected] (A.M.B.-d.-C.); ngomes@ff.up.pt (N.G.M.G.); [email protected] (Á.M.-C.) 2 UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 3 LAQV-REQUIMTE, Laboratory of Pharmacognosy, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 4 Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal * Correspondence: [email protected] (D.D.-d.-S.); [email protected] (R.J.D.-O.); Tel.: +351-224-157-216 (R.J.D.-O.) Received: 21 September 2020; Accepted: 20 October 2020; Published: 23 October 2020 Abstract: Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids.
    [Show full text]